Search Results 811-820 of 17088 for saffron dosage

1. A Study to Evaluate the Effectiveness and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema in Adolescents and Adults - Mayo Clinic

   ... dosages and risks/benefits. In the later phase (phase 3), researchers study ... dose antihistamine (cetirizine 40 mg/day or equivalent high-dose second ...

2. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

   ... dosages and risks/benefits. In the later phase (phase 3), researchers ... dose reduction should be done at least 7 days prior to first dose. Prior ...

3. A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors - Mayo Clinic

   ... dosages and risks/benefits. In the later phase (phase 3), researchers study ... dose of study drug. Male patients with female sexual partners of ...

4. General Internal Medicine - Clinical trials

   ... dose selection and basket design with exploratory single-arm cohorts for various subpopulations of participants. Alleviation by Fisetin of Frailty ...

5. The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant ...

6. Medical Research & Education - Mayo Clinic News Network

   Study: 1 dose of non-prescribed Adderall raises blood pressure, heart rate in. Cardiovascular. Study: 1 dose of non-prescribed Adderall raises blood ...

7. Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary ...

8. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   ... dosages and risks/benefits. In the later phase (phase 3), researchers study ... dose of atezolizumab, 30 days after the last dose of nab-paclitaxel, or ...

9. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction - Mayo Clinic

   This phase I trial studies the side effects and the best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction.

10. Clinical trials - Oncology (Medical)

    The purpose of this study is to determine the recommended doses (RD) and dosing regimens of [ 177Lu]Lu-NeoB in combination with capecitabine in adult ...